FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer

Cell Cycle

Volumn 11, Issue 15, 2012, Pages 2947-2955

  Panneerselvam, Jayabal ^a   Park, Hwan Ki ^b,d,e   Zhang, Jun ^b   Dudimah, Fred Duafalia ^a   Zhang, Piyan ^b   Wang, Hong ^b,c   Fei, Peiwen ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF HAWAII   (United States)

^e Kyungpook National University   (South Korea)

Author keywords

Bladder cancer; Cell invasiveness; Chromosomal instability; FAVL; The FA tumor suppressor pathway

Indexed keywords

FANCONI ANEMIA GROUP L PROTEIN; MITOMYCIN C; UNCLASSIFIED DRUG; VARIANT OF FANCONI ANEMIA GROUP L PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA DAMAGE; FANCONI ANEMIA; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION;

EID: 84864557092     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21400     Document Type: Article

References (66)

1. Jemal A, et al. Cancer genetics. CA: a Cnacer Journal of Clinicians 2007; 57:43-66; http://dx.doi.org/10.3322/canjclin.57.1.43.
2. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007; 25:563-71; PMID:17710407; http://dx.doi. org/10.1007/s00345-007-0197-0.
3. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007; 25:5352-8; PMID:18048815; http://dx.doi.org/10.1200/JCO.2006.10.4125.
4. Jee HJ, Kim AJ, Song N, Kim HJ, Kim M, Koh H, et al. Nek6 overexpression antagonizes p53- induced senescence in human cancer cells. Cell Cycle 2010; 9:4703-10; PMID:21099361; http://dx.doi.org/10.4161/cc.9.23.14059.
5. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25:9-34; PMID:16680569; http://dx.doi.org/10.1007/ s10555-006-7886-9.
6. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001; 8:9-15; PMID:11115562.
7. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57:5281-5; PMID:9393750.
8. Chow NH, Liu HS, Yang HB, Chan SH, Su IJ. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch 1997; 430:461-6; PMID:9230911; http://dx.doi.org/10.1007/s004280050056.
9. Sayan AE, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K, et al. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 2012; 31:1493-503; PMID:21822309; http://dx.doi.org/10.1038/onc.2011.336.
10. Sugano G, Bernard-Pierrot I, Laé M, Battail C, Allory Y, Stransky N, et al. Milk fat globule - epidermal growth factor - factor VIII (MFGE8)/lactadherin promotes bladder tumor development. Oncogene 2011; 30:642-53; PMID:20956946; http://dx.doi.org/10.1038/onc.2010.446.
11. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011; 30:178-89; PMID:20818428; http://dx.doi.org/10.1038/ onc.2010.399.
12. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can cooperate with E17K. Oncogene 2010; 29:150-5; PMID:19802009; http://dx.doi.org/10.1038/onc.2009.315.
13. Sengerová B, Wang AT, McHugh PJ. Orchestrating the nucleases involved in DNA interstrand crosslink (ICL) repair. Cell Cycle 2011; 10:3999-4008; PMID:22101340; http://dx.doi.org/10.4161/cc.10.23.18385.
14. Bagby GC Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol 2003; 10:68-76; PMID:12483114; http://dx.doi.org/10.1097/00062752-200301000-00011.
15. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107:4223-33; PMID:16493006; http://dx.doi.org/10. 1182/blood-2005-10-4240.
16. Huang TT, D'Andrea AD. Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006; 7:323-34; PMID:16633336; http://dx.doi.org/10.1038/ nrm1908.
17. Fei P, Yin J, Wang W. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle 2005; 4:80-6; PMID:15611632; http://dx.doi.org/10.4161/cc.4. 1.1358.
18. Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006; 8:339-47; PMID:16531995; http://dx.doi.org/10.1038/ncb1378.
19. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8:735-48; PMID:17768402; http://dx.doi.org/10.1038/nrg2159.
20. D'Andrea AD. The Fanconi road to cancer. Genes Dev 2003; 17:1933-6; PMID:12893780; http://dx.doi.org/10.1101/gad.1128303.
21. D'Andrea AD, Grompe M. The Fanconi anaemia/ BRCA pathway. Nat Rev Cancer 2003; 3:23-34; PMID:12509764; http://dx.doi.org/10.1038/nrc970.
22. Zhang J, Zhao D, Park HK, Wang H, Dyer RB, Liu W, et al. FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest 2010; 120:1524-34; PMID:20407210; http://dx.doi.org/10.1172/JCI40908.
23. Zhang J, Wang X, Lin CJ, Couch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther 2006; 5:1632-6; PMID:17106252; http://dx.doi.org/10.4161/cbt.5.12.3351.
24. Zhang J, Zhao D, Wang H, Lin CJ, Fei P. FANCD2 monoubiquitination provides a link between the HHR6 and FA-BRCA pathways. Cell Cycle 2008; 7:407-13; PMID:18277096; http://dx.doi.org/10.4161/cc.7.3.5156.
25. Park HK, Wang H, Zhang J, Datta S, Fei P. Convergence of Rad6/Rad18 and Fanconi anemia tumor suppressor pathways upon DNA damage. PLoS ONE 2010; 5:e13313; PMID:20967207; http://dx.doi.org/10.1371/journal.pone.0013313.
26. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003; 35:165-70; PMID:12973351; http://dx.doi.org/10.1038/ng1241.
27. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74; PMID:12692539; http://dx.doi.org/10. 1038/nm852.
28. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-21; PMID:12569143; http://dx.doi.org/10.1093/jnci/95.3.214.
29. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 2005; 37:958-63; PMID:16116422; http://dx.doi.org/10.1038/ng1626.
30. Reid SSD, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39:162-4; PMID:17200671.
31. Roest HP, Baarends WM, de Wit J, van Klaveren JW, Wassenaar E, Hoogerbrugge JW, et al. The ubiquitin-conjugating DNA repair enzyme HR6A is a maternal factor essential for early embryonic development in mice. Mol Cell Biol 2004; 24:5485-95; PMID:15169909; http://dx.doi.org/10.1128/MCB.24.12.5485-5495. 2004.
32. Xia BDJ, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007; 39:159-61; PMID:17200672.
33. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011; 43:142-6; PMID:21240275; http://dx.doi.org/10.1038/ng.750.
34. Levy-Lahad E. Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 2010; 42:368-9; PMID:20428093; http://dx.doi.org/10.1038/ng0510-368.
35. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42:410-4; PMID:20400964; http://dx.doi.org/10.1038/ng.569.
36. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011; 43:138-41; PMID:21240277; http://dx.doi.org/10.1038/ng.751.
37. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42:406-9; PMID:20400963; http://dx.doi.org/10.1038/ng.570.
38. Rahman NSS, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, et al. Breast Cancer Susceptibility Collaboration (UK). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39:165-7; PMID:17200668.
39. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J 2007; 26:2104-14; PMID:17396147; http://dx.doi.org/10. 1038/sj.emboj.7601666.
40. Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 2007; 25:331-43; PMID:17289582; http://dx.doi.org/10.1016/ j.molcel.2007.01.003.
41. Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J Hum Genet 1999; 65:1330-41; PMID:10521298; http://dx.doi. org/10.1086/302627.
42. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297:606-9; PMID:12065746; http://dx.doi.org/10.1126/science.1073834.
43. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14:320-3; PMID:8896563; http://dx.doi.org/10.1038/ng1196-320.
44. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992; 356:763-7; PMID:1574115; http://dx.doi.org/10.1038/356763a0.
45. de Winter JP, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000; 24:15-6; PMID:10615118; http://dx.doi.org/10.1038/71626.
46. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001; 7:241-8; PMID:11239453; http://dx.doi.org/10.1016/S1097-2765(01)00172-1.
47. Levitus M, Rooimans MA, Steltenpool J, Cool NF, Oostra AB, Mathew CG, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 2004; 103:2498-503; PMID:14630800; http://dx.doi.org/10.1182/blood-2003-08-2915.
48. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002; 109:459-72; PMID:12086603; http://dx.doi.org/10.1016/S0092- 8674(02)00747-X.
49. rd, Hurov KE, Luo J, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007; 129:289-301; PMID:17412408; http://dx.doi.org/10.1016/j.cell.2007.03.009.
50. Sala-Trepat M, Rouillard D, Escarceller M, Laquerbe A, Moustacchi E, Papadopoulo D. Arrest of S-phase progression is impaired in Fanconi anemia cells. Exp Cell Res 2000; 260:208-15; PMID:11035915; http://dx.doi.org/10.1006/ excr.2000.4994.
51. Grompe M. FANCL, as in ligase. Nat Genet 2003; 35:113-4; http://dx.doi.org/10.1038/ng1003-113.
52. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22:719-29; PMID:16793542; http://dx.doi.org/10.1016/j.molcel.2006.05.022.
53. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005; 37:934-5; PMID:16116423; http://dx.doi.org/10.1038/ng1625.
54. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8:255-65; PMID:16153896; http://dx.doi.org/10. 1016/j.ccr.2005.08.004.
55. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003; 97:425-40; PMID:12518367; http://dx.doi.org/10.1002/cncr.11046.
56. Williams DA, Croop J, Kelly P. Gene therapy in the treatment of Fanconi anemia, a progressive bone marrow failure syndrome. Curr Opin Mol Ther 2005; 7:461-6; PMID:16248281.
57. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005; 5:543-55; PMID:15965494; http://dx.doi.org/10.1038/nrc1648.
58. Kennedy RD, D'Andrea AD. The Fanconi Anemia/ BRCA pathway: new faces in the crowd. Genes Dev 2005; 19:2925-40; PMID:16357213; http://dx.doi. org/10.1101/gad.1370505.
59. Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature 1971; 230:370-3; PMID:4927726; http://dx.doi.org/10.1038/230370a0.
60. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976; 261:494-6; PMID:934283; http://dx.doi.org/10.1038/261494a0.
61. Alter BP. Aplastic Anemia, Pediatric Aspects. Oncologist 1996; 1:361-6; PMID:10388017.
62. Meetei AR, Yan Z, Wang W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 2004; 3:179-81; PMID:14712086; http://dx.doi.org/10.4161/cc.3.2.656.
63. Rego MA, Harney JA, Mauro M, Shen M, Howlett NG. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 2012; 31:366-75; PMID:21685936; http://dx.doi.org/10.1038/ onc.2011.237.
64. Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, Hoatlin ME, et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008; 27:3641-52; PMID:18212739; http://dx.doi.org/10.1038/sj.onc.1211034.
65. Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, et al. Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway. Oncogene 2008; 27:4798-808; PMID:18438432; http://dx.doi.org/10.1038/onc.2008.121.
66. Park HK, Panneerselvam J, Dudimah FD, Dong G, Sebastian S, Zhang J, et al. Wip1 contributes to cell homeostasis maintained by the steadystate level of Wtp53. Cell Cycle 2011; 10:2574-82; PMID:21734451; http://dx.doi.org/10.4161/cc. 10.15.15923.